Summary & Overview
HCPCS A9615: Injection, pegulicianine, 1 mg
HCPCS Level II code A9615 denotes the injectable drug pegulicianine, billed per 1 mg unit. This code is relevant for outpatient and ambulatory settings where pegulicianine is administered as a procedural or therapeutic injectable. Nationally, precise coding for specialty injectables like pegulicianine affects billing accuracy, payment consistency, and tracking of utilization for novel agents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the service type. The publication also summarizes payer coverage considerations, common billing modifiers, and areas where practitioners and billing teams often need clarity.
This report provides benchmarks and policy-relevant context for billing pegulicianine, outlines payer-specific coding practices where available, and highlights clinical contexts in which the injection is used. Data not available in the input will be explicitly noted in relevant sections.
Billing Code Overview
HCPCS Level II code A9615 represents Injection, pegulicianine, 1 mg. This code describes a parenteral pharmaceutical product administered as an injectable dosage form where each unit of billing corresponds to 1 mg of pegulicianine.
Service Type: Therapeutic/Procedural injectable medication
Typical Site of Service: Outpatient infusion or ambulatory care setting, including hospital outpatient departments and ambulatory surgical centers where injectable oncologic or diagnostic agents are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to an outpatient retinal specialty clinic for evaluation and treatment of suspected or recurrent neovascular (wet) age-related macular degeneration (AMD). After informed consent and baseline ophthalmic imaging—including optical coherence tomography (OCT) and fluorescein angiography—the ophthalmologist administers an intravitreal injection of A9615 (pegulicianine, 1 mg) as an adjunctive or primary intravitreal therapeutic agent during a clinic procedure. The clinical workflow includes: pre-procedure consent and medication verification, topical anesthesia and antisepsis, measurement of intraocular pressure as indicated, sterile intravitreal injection technique, post-injection monitoring for acute complications (pain, hemorrhage, elevated intraocular pressure, endophthalmitis), and arrangement for follow-up imaging and visits within 1–4 weeks. Typical site of service is an ophthalmology outpatient clinic or ambulatory surgical center for patients requiring procedural sedation or more controlled sterile conditions. Common patient comorbidities include hypertension, diabetes mellitus, and anticoagulant use, which may affect peri-procedural management and documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default | Use when no special circumstances apply and a standard intravitreal injection was performed. |